Details for Patent: 7,700,645

Title:	Pseudopolymorphic forms of a HIV protease inhibitor
Abstract:	New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sul- fonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.
Inventor(s):	Vermeersch; Hans Wim Pieter (Ghent, BE), Thone; Daniel Joseph Christiaan (Beerse, BE), Janssens; Luc Donne Marie-Louise (Malle, BE)
Assignee:	Tibotec Pharmaceuticals Ltd. (Little Island, Co. Cork, IE)
Filing Date:	May 16, 2003
Application Number:	10/514,352
Claims:	1. An ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sul- fonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1. 2. A solvate having the formula: ##STR00002## 3. A composition comprising an ethanolate solvate of the compound (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sul- fonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate, in which the ratio of compound to ethanol is about 1:1, and an inert carrier. 4. The composition of claim 3 wherein the inert carrier is a pharmaceutically acceptable carrier. 5. The composition of claim 4 wherein the pharmaceutically acceptable carrier is a solid inert carrier. 6. A composition comprising a solvate having the formula: ##STR00003## and an inert carrier. 7. The composition of claim 6 wherein the inert carrier is a pharmaceutically acceptable earner. 8. The composition of claim 7 wherein the pharmaceutically acceptable carrier is a solid inert carrier.